Modern-day cardio-oncology: a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’

22Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

During the ‘Heart Failure and World Congress on Acute Heart Failure 2018’, many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the ‘Heart Failure and World Congress on Acute Heart Failure 2018’. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.

Author supplied keywords

Cite

CITATION STYLE

APA

Anker, M. S., Lena, A., Hadzibegovic, S., Belenkov, Y., Bergler-Klein, J., de Boer, R. A., … Lyon, A. R. (2018, December 1). Modern-day cardio-oncology: a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018.’ ESC Heart Failure. Wiley-Blackwell. https://doi.org/10.1002/ehf2.12386

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free